Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Efficacy of antiangiogenic medication to treat arteriovenous malformations

In a prospective experimental observational study of 18 individuals with severe, recurrent extracranial arteriovenous malformations, thalidomide was effective in reducing pain, healing ulceration, stopping bleeding and resolving cardiac failure.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Clinical and radiological response to thalidomide.


  1. Liu, A. S., Mulliken, J. B., Zurakowski, D., Fishman, S. J. & Greene, A. K. Extracranial arteriovenous malformations: natural progression and recurrence after treatment. Plast. Reconstr. Surg. 125, 1185–1194 (2010). Original publication with a large series describing the natural evolution of extracranial AVMs.

    Article  CAS  Google Scholar 

  2. Burrows, P. E., Mulliken, J. B., Fishman, S. J., Klement, G. L. & Folkman, J. Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child. J. Craniofac. Surg. 20, 597–602 (2009). A case study demonstrating, for the first time, the efficacy of medical treatment of AVM using a metalloproteinase inhibitor.

    Article  Google Scholar 

  3. Lebrin, F. et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat. Med. 16, 420–428 (2010). Original publication demonstrating efficacy of thalidomide in reducing epistaxis (nosebleed) in hereditary hemorrhagic telangiectasia.

    Article  CAS  Google Scholar 

  4. Van Damme, A., Seront, E., Dekeuleneer, V., Boon, L. M. & Vikkula, M. New and emerging targeted therapies for vascular malformations. Am. J. Clin. Dermatol. 21, 657–668 (2020). A review article on theragnostic medical therapy for vascular anomalies based on the involved underlying molecular pathways.

    Article  Google Scholar 

  5. Boscolo, E. et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J. Clin. Invest. 125, 3491–3504 (2015). Original publication demonstrating efficacy of preclinical and clinical medical treatment of slow-flow vascular anomalies with rapamycin.

    Article  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Boon, L. M. et al. Case report study of thalidomide therapy in 18 patients with severe arteriovenous malformations. Nat. Cardiovasc. Res. (2022).

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Efficacy of antiangiogenic medication to treat arteriovenous malformations. Nat Cardiovasc Res 1, 552–553 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research